Member Info for Moneymunch

Back on track, UPward momentum in anticipation of a run of positive newsflow and potential significant re-rate, expected soon!!! Gla holders :-)

Cheers Porter, obviously gearing UP for a busy period ahead and hopefully be too long before the next UPdate or two on progress made. In Eric we trust. Gl :-)

Https://genflowbio.com/vacancy/senior-scientist/

Vera Gorbunova & Eric Verdin are both presenting. Gla ;-)

hTtps://agingpharma.org/

.......

Announcing Longevity Science Foundation as tier 5 sponsor of ARDD 2024

Empowering the future of aging research: Longevity Science Foundation to sponsor ARDD 2024, the world's largest conference on aging research in the biopharmaceutical industry

Business Announcement

Aging Research and Drug Discovery

The University of Copenhagen is excited to announce Longevity Science Foundation as a Tier 5 Sponsor of the 11th Aging Research & Drug Discovery Meeting, the world's largest conference on aging research in the biopharmaceutical industry that will transpire on August 26 - August 30, 2024 on-site at the Ceremonial Hall, University of Copenhagen, and online.

..........

ARDD 2024 is set to feature a stellar lineup. The Longevity Science Foundation, along with esteemed academic institutions, clinicians, industry leaders, investors, and pharmaceutical companies, will contribute to rich dialogues and present new research in the field of aging. This year, ARDD is proud to be a partner of XPRIZE Healthspan, a 7-year, $101 million global competition to revolutionize the way we approach human aging. Highlighting this collaboration, XPRIZE Healthspan will host its first XPRIZE Healthspan Team Summit at the 11th ARDD. The event underscores a shared commitment between ARDD and XPRIZE to fostering advancements in health and longevity, signaling an important milestone in efforts to enable everyone to live healthier and longer lives through extended healthspan.

“I’m extremely excited about this year's ARDD. We have a stellar academic lineup and an incredibly strong presence from leading companies in the aging field. This year the presence of pharma companies including Lilly, Lundbeck, Novartis, Regeneron and many others have been strengthened and we are super excited that XPRIZE will host their XPRIZE Healthspan Team Summit at ARDD.

htTps://www.eurekalert.org/news-releases/1048285

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,687 followers

6h

Earlier this year, Genflow Biosciences (LON:GENF) (OTCQB:GENFF) Biosciences was named “a firm to watch” by @TheGuardian, substantiating the results of their MASH studies this past year.

Dr. Eric Leire, CEO and Founder of Genflow said, “Some people are lucky to have the good gene, and what we want to do is share that luck with everybody.” The “good gene,” refers to #SIRT6, which plays an important role in longer #healthspans.

As Genflow conquers the #biotech world, the company also offers investors an exciting investment case with:

✅Large Market opportunity: 35 million globally, keeping the door open to broaden anti-aging.

✅Long Life IP: two patent families

✅Robust Pipeline: advancing developmental programs

Find more information here: hTtps://loom.ly/NQrjPyw

#genes #longevity #healthspan #GENF

Hopefully not long Porter, for the next run of newsflow and upward momentum in sp. It was disappointing we didn't kick on from 3.3p , but maybe this time the UPside will be even more significant with such a tight free float and the rest of the shares tightly held. Gl :-)

Big news at anytime Porter, with plenty of positive newsflow expected soon. Gl ;-)

1.20230018934METHOD OF IN VIVO ADMINISTRATION OF THE CODING SEQUENCE OF THE SIRT6 GENE VIA ADENO-ASSOCIATED VIRUS

US - 19.01.2023

Int.Class

A61K 48/00

Appl.No 17865688

Applicant GENFLOW BIOSCIENCES SRL

Inventor Eric LEIRE

Methods for in vivo administration of the coding sequence of the sirt6 gene. In particular, methods that include the administration of adeno-associated virus vectors or recombinant adeno-associated virus vectors including the coding sequence of the sirt6 gene.

.......

.WO/2024/121363VARIANTS OF SIRTUIN 6 FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE

WO - 13.06.2024

Int.Class

A61K 38/43

Appl.No PCT/EP2023/084840

Applicant GENFLOW BIOSCIENCES SRL

Inventor VINCIGUERRA, Manlio

The present invention relates to variants of sirtuin 6 for the treatment of non-alcoholic fatty liver disease.

......

.4338267VARIANTS OF SIRT6 FOR USE IN PREVENTING AND/OR TREATING AGE-RELATED DISEASES

EP - 20.03.2024

Int.Class

H02K 7/18

Appl.No 22808414

Applicant UNIV ROCHESTER

Inventor GORBUNOVA VERA

The present invention relates to an isolated nucleic acid molecule encoding a variant of sirtuin 6 (SIRT6) having at least 75% identity with sequence SEQ ID NO: 1, the variant having at least one mutation selected in the group comprising or consisting of a N308K substitution and a A313S substitution with respect to sequence SEQ ID NO: 1. The invention provides means for the regulation of ageing, and/or senescence, and/or lifespan in an individual. The invention further provides means for the repair of double strand breaks in a cell. Finally, the invention also provides means for the prevention and/or the treatment of an age-related disease.

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,686 followers

18h

In the world of #biotech, safety must be of the utmost concern. At Genflow Biosciences (LON:GENF) (OTCQB:GENFF), we have systems in place to enhance safety across our innovative #SIRT6 trials.

Our patent-pending tech allows for non-replicating, safe transient expression of genes, minimizing risks while maximizing potential benefits.

In simpler terms, we have created methods that temporarily activate the crucial SIRT6 gene without permanently altering the DNA, ensuring both safety and efficacy for therapeutic applications.

To learn more about our protocols, click here: htTps://loom.ly/uh0pGy8

A biotechnological powerhouse for anti ageing treatments | Genflow

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,684 followers

1w

The biotech market has had another resurgence of interest this year, marked by increased hopes that the first round of interest rate cuts will come soon.

Positioned to capitalize on this are companies in high growth markets, such as Genflow Biosciences (LON:GENF) (OTCQB:GENFF), a leader in aging research, which continues to innovate with its cutting edge #SIRT6 therapeutics.

Read more about the rally: htTps://shorturl.at/qqhWt

Shots in the arm for Britain and biotech

Investment trusts to target recoveries in the UK and biotech.

July 25, 2024

UK re-rate long overdue.

Signs of recovery in biotech.

Two of the big sound bites of recent years were “broken Britain” and “trust the science.” From an investment perspective it may be time to discard the first and keep faith in the second of these phrases. Following a tough decade there are some deep value opportunities especially among smaller UK-listed companies. In the case of life sciences and biotechnology, the industry is showing signs of recovering health after valuations and fundraising were hit by the period of rapid interest rate hikes.

Recent PMI data, especially in manufacturing, suggests that the UK recovery is on track. Greater political certainty is widely perceived as being of benefit in encouraging companies to make capex decisions which will provide a further boost to UK growth. Of course, the flipside of increased demand for resources and labour is that this can have an inflationary effect in the short term, but not necessarily in the components of indicators that are worrying policymakers.

htTps://www.investorschronicle.co.uk/content/45b6d8c8-36b1-51a3-a971-528b5bdbc3a2

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,683 followers

7h

The pet care industry has exploded in recent years, with dog focused products seizing the majority of the market.

Treatments promising to extend canine companions' lifespans, such as Genflow Biosciences (LON:GENF) (OTCQB:GENFF) innovative #SIRT6 treatment, are gaining significant attention from animal lovers and investors alike.

Learn more about the promising treatments: htTps://loom.ly/hTB3OGE

#longevity #veterinarymedicine #biotech

The next leap in pet health: longevity drugs for dogs

htTps://www.labiotech.eu/in-depth/longevity-drugs-for-dogs/

Looking forward to the bounce in sp, big news could drop at anytime. Gla Holders:-)

Britain can become the global leader in longevity science, Lord Lebedev has told Parliament.

23/7/24

Longevity research ‘can unlock huge benefits’ for Britain as it tackles an ageing population

‘As life expectancy has increased, the proportion of time spent in good health is going down. We must urgently develop a new approach to medicine’ - Lord Lebedev

He stressed that longevity research could “unlock huge benefits” for the UK as it faces the challenges of an ageing population. “Our country faces a medical crisis,” he said. “As life expectancy has increased, the proportion of time spent in good health is going down. We must urgently develop a new approach to medicine.”

......

“The discovery of the 12 hallmarks of ageing, including the loss of stem cells and metabolic dysregulation, are central to our understanding of what drives age-related disease,” the crossbench peer told the Upper House.

“A groundbreaking new theory suggests ageing is driven by the loss of vital regulatory information within our cells, rather than primarily accumulating damage over time. Through epigenetic reprogramming, we could potentially reset our body’s tissues to a more functional state. Scientific studies have already reversed vision loss in mice and human trials are set to begin next year.”

The peer highlighted drugs being developed to reverse aspects of ageing.

“Cutting-edge breakthroughs like these, driven by labs right here in the UK, are informing how we tackle the underlying factors behind ageing, rather than just tackling symptoms,” he added. He stressed further: “We stand at the precipice of a medical revolution, catalysed by medical monitoring devices, genomics, and our understanding of what drives ageing.

“Britain can become the global leader in longevity science, and capturing this beachhead will benefit us both socially and economically.” He emphasised that the science is now “moving as rapidly as the AI revolution and will be similarly, if not more impactful”.

hTtps://www.standard.co.uk/news/politics/longevity-research-benefits-population-lord-lebedev-speech-b1172354.html

I'm pretty sure, just about every share that's been sold over the last couple of weeks or so, bringing the sp down to where it is, despite the low and insignificant selling volume, have been bought, alomost under the radar!!!??? Gla holders and C'mon England!!! :')))

Cheers Porter, very encouraging potential validation for Genflow's cutting edge science and hopefully not long before the next UPdate or two, to get the sp back to 3p plus and more, and every chance of something even bigger in the pipeline given the significant share accumulation we've witnessed over the last few months, such as a Major JV partner planned/required for the dog trials and/or a Major player interested in the rest of the pipeline/science.

Gl :-)

The following publication only just released is by the Duke University School of Medicine, one of Genflow's academic collaborative partners, focused on "ferroptosis" which appears to be highly influenced by Sirt6. Gla holders. :-)

Researchers successfully rejuvenate aging livers in preclinical study

July 8, 2024 —

Researchers have been able to reverse age-related damage to liver cells in mice and in human cell cultures in a new study.

The study homes in on ferroptosis — a form of iron-dependent cell death — as an age-related process affecting a set of key cells in the liver, called ‘hepatocytes.’

Its authors found gene clusters associated with this process in both mice and human cells.

The takeaway is that it may be possible to reverse aging in affected liver cells through pharmaceutical interventions.

hTtps://www.medicalnewstoday.com/articles/researchers-successfully-rejuvenate-aging-livers-in-preclinical-study

.....

The roles of sirtuins in ferroptosis

htTps://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2023.1131201/full

Accumulation of cheap shares that have bee sold since Monday last week. No free float left in any volume as the majority are held very tightly imho and so you can imagine the sp response on any big news arriving. Gl :-)

No chance of sub 2p imho, looks like the cheap shares are being mopped UP in time for the next rise. Gla holders:-)

Although somewhat disappointing to see the retrace, I'm holding on to all of mine as well Porter, big news could drop at anytime and back to 3p plus and more in a blink. There's plenty of news expected Q2 and so shouldn't be too long before the buyers arrive in anticipation of bigger and better things to come. Gl :-)

Low volume selling pi's dragging the sp down as we await the next UPdate, and will hopefully all regret selling their shares soon enough. Big news at anytime. Gla Holders!!! ;-)